Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes

Akoğlu, Gülşen

doi:10.4103/0253-7613.129326

Cited by 7 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rapid expansion of novel anticancer agents has resulted in significant advances in the treatment of cancer patients but has also broadened the spectrum of cutaneous adverse events. Conventional chemotherapeutic agents are well known to cause cutaneous reactions including hand‐foot syndrome (palmoplantar erythrodysesthesia), neutrophilic eccrine hidradenitis, radiation recall dermatitis, alopecia, hyperpigmentation, urticarial hypersensitivity reaction and sclerotic reactions among many others. Although the classic cutaneous reactions associated with chemotherapy agents are well known, the histopathologic characteristics of reactions caused by the many novel anticancer agents are under‐recognized.…”

mentioning

confidence: 99%

Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma

et al. 2016

View full text Add to dashboard Cite

The histopathologic characteristics of reactions caused by the many novel anticancer agents are under-recognized. We report a case of a 67-year-old female with locally advanced metastatic breast cancer, who initially presented with an extensive reticulated erythematous patch on the trunk caused by intravascular metastases confirmed by a skin biopsy. Due to disease progression, she was started on ixabepilone, a mitotic inhibitor. While receiving ixabepilone, another skin biopsy was obtained and initially interpreted as extramammary Paget’s disease. However, the biopsy showed metaphase arrest of numerous keratinocytes in the basilar and suprabasilar epidermis. Atypical epithelial cells were only present in the intravascular spaces similar to the initial biopsy. Given the temporal association between the initiation of ixabepilone therapy and the epidermal mitotic arrest, a diagnosis of chemotherapy reaction to ixabepilone was rendered. Ixabepilone is an analog of epothilone, a microtubule stabilizer causing mitotic arrest of the cell cycle approved for the treatment of metastatic and locally advanced treatment-resistant breast cancer. The demonstration of epidermal mitotic arrest caused by ixabepilone is without precedent. The case emphasizes the importance of considering a chemotherapy reaction in the histologic differential diagnosis of epidermal mitotic arrest in a cancer patient receiving chemotherapy.

show abstract

mentioning

confidence: 99%

Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Nos 29 estudos identificados nesta revisão sistemática, n=26 (90%) apresentaram alternativas de tratamento e/ou prevenção, tanto farmacológico como não farmacológico, para pacientes acometidos com a síndrome mãopé [15][16][17][18][19][20][22][23][24][25][26][27][28][29][30][31][32] . A maioria dos manejos para tratamento da síndrome mão-pé publicados foi de relatos de casos.…”

Section: Discussionunclassified

“…A síndrome mão-pé é uma reação adversa muito comum durante o tratamento com agentes quimioterápicos e é um fator preditor de morbidade e mortalidade, uma vez que as lesões são portas de entrada para instalação de microrganismos e, dessa forma, implica em risco de sepse [29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47] .…”

Section: Discussionunclassified

Identificação, Prevenção e Tratamento da Síndrome Mão-Pé Induzida por Quimioterapia: Revisão Sistemática

Pereira

Pedroso

Ribeiro

2020

Rev. Brasileira.De.Cancerologia

View full text Add to dashboard Cite

Introdução: A síndrome mão-pé é uma reação adversa experimentada por vários pacientes em tratamento para o câncer e fator preditor de morbidade e mortalidade. Objetivo: Avaliar as evidências científicas relacionadas à identificação, prevenção e tratamento da síndrome mão-pé induzida por agentes quimioterápicos, identificar os principais sinais e sintomas que possibilitam o reconhecimento da síndrome e, ainda, discutir a ocorrência de onicomicoses no contexto da síndrome mão-pé. Método: Trata-se de uma revisão sistemática na MEDLINE/PubMed, Biblioteca Virtual da Saúde e Scopus, incluindo literatura cinzenta e busca manual. Os 29 estudos incluídos na revisão foram analisados e classificados segundo a hierarquia dos níveis de evidência Grading of Recommendations Assessment, Development and Evaluations (GRADE) e a confiabilidade entre os examinadores (coeficiente Kappa) foi calculada. Resultados: Foram identificados estudos que demonstraram eficácia na prevenção da síndrome mão-pé com o uso da crioterapia e hidroterapia. Evidenciaram-se resultados satisfatórios com o uso do creme de ureia na prevenção e tratamento, e o uso de piridoxina não apresentou resultados conclusivos. Foram encontrados mecanismos para identificação da síndrome e para classificação dos agentes indutores. O grupo dos taxanos predominou entre os medicamentos indutores da síndrome mão-pé. Conclusão: Existem evidências consistentes, porém não contemplam todos os fármacos indutores da síndrome e não exploram outras manifestações relacionadas às onicólises e onicomicoses. O estudo apresentou resultados que poderão auxiliar os prescritores na identificação da síndrome mão-pé, além de alternativas para prevenção e tratamento. Contudo, vale destacar a necessidade de pesquisas futuras para elucidar a etiologia e protocolos de tratamento.

show abstract

“…The onset of onychopathy induced by DTX reflects dose-dependent cumulative toxicity [ 7 ] and the accumulation rate also represents an important factor predicting the severity of this adverse event. Previous studies have shown wide variation in the time of onset of onychopathy; this has therefore been difficult to predict and tended to be overlooked, resulting in late diagnosis at a severe stage, and treatment by dosage reduction or discontinuation [ 8 ]. Minisini [ 4 ] and Takeshita et al [ 9 ] reported that DTX-associated onychopathy was present at earlier time-points than those reported by clinical trials and emphasized that early treatment was important.…”

Section: Discussionmentioning

confidence: 99%

A novel predictive factor for the onset time of docetaxel-induced onychopathy: a multicenter retrospective study

Takahata

Tanabe

Takaki

et al. 2016

J Pharm Health Care Sci

View full text Add to dashboard Cite

BackgroundTaxanes are known to cause onychopathy. Previous studies have reported the relationship between onychopathy and paclitaxel dosing intervals and cumulative doses. However, there are no studies of the predictive factors for docetaxel-induced nail changes. The present study used the drug accumulation rate (mg/m2/day) as a novel indicator and evaluated its usefulness for the prediction of onychopathy.MethodsFrom January 2008 to December 2009, we examined patients who received docetaxel at the Toyama University Hospital and Tonami General Hospital to determine the time to onset of onychopathy, the accumulation rate, and the cumulative dose. We then divided the study subjects into two groups, and used Receiver Operating Characteristic (ROC) analysis to calculate a cut-off value. We evaluated both indicators as predictive factors for onychopathy using the log-rank test and Cox proportional hazards model.ResultsNinety-five patients were included in the present study. The results of the log-rank test sub-analysis revealed that the median number of days until onychopathy onset was significantly shorter in patients with an accumulation rate greater than the cut-off (P = 0.009), and in those with a cumulative dose below the cut-off (P < 0.001). The hazard ratios for the accumulation rate and cumulative dose, evaluated using Cox proportional hazards regression analysis, were 1.44 (P = 0.036) and 0.99 (P < 0.001), respectively.ConclusionsThe results of the present study indicated that the drug accumulation rate influenced the time to onset of docetaxel-induced onychopathy.Trial registrationThis study is not applicable for trial registration due to retrospective chart review without intervention.

show abstract

Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes

Cited by 7 publications

References 7 publications

Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma

Chemotherapy reaction induced by ixabepilone, a microtubule stabilizing agent, mimicking extramammary Paget's disease in a patient with breast carcinoma

Identificação, Prevenção e Tratamento da Síndrome Mão-Pé Induzida por Quimioterapia: Revisão Sistemática

A novel predictive factor for the onset time of docetaxel-induced onychopathy: a multicenter retrospective study

Contact Info

Product

Resources

About